Lab
Quest Diagnostics LLC Il
Quest Diagnostics LLC Il was paid $50.71M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 24% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS LLC IL
SCHAUMBURG, IL 60173
SCHAUMBURG, IL 60173
33aNPI1346389764assigned 02/05/2007
33bProvider typeClinical Medical Laboratory
28Total paid$50.71M
24GClaims1,321,771
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Illinois
Rank by total paid#3 of 235
Median peer was paid$123K
This provider vs. median413×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 118,413 | $3.85M | |
| 2019 | 130,187 | $4.34M | |
| 2020 | 136,858 | $6.08M | |
| 2021 | 238,229 | $10.49M | |
| 2022 | 285,069 | $10.51M | |
| 2023 | 220,412 | $8.32M | |
| 2024incomplete | 192,603 | $7.12M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 24% | 165,438 | 136,660 | $12.41M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 18% | 260,516 | 227,538 | $9.24M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 18% | 258,434 | 228,799 | $9.14M |
| 81513 | 8.0% | 47,298 | 39,465 | $4.03M | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 5.6% | 113,090 | 99,337 | $2.86M |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 5.2% | 64,548 | 56,002 | $2.62M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 4.0% | 88,416 | 74,213 | $2.04M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3.1% | 63,187 | 56,973 | $1.56M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.5% | 71,591 | 67,546 | $1.28M |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 2.0% | 30,302 | 21,571 | $1.01M |
| 87536 | 2.0% | 13,696 | 12,867 | $996K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.5% | 6,301 | 5,817 | $768K |
66 more codes
| 87522 | Neg quan hep c or qual rna | <1% | 12,186 | $402K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,230 | $346K |
| 87480 | <1% | 14,668 | $314K | |
| 87510 | <1% | 14,639 | $313K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,834 | $260K |
| 87660 | <1% | 14,295 | $207K | |
| 88142 | <1% | 20,549 | $132K | |
| 88141 | <1% | 11,362 | $116K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 19,776 | $104K |
| 88112 | <1% | 2,605 | $103K | |
| 87631 | <1% | 744 | $69K | |
| 87517 | <1% | 1,747 | $67K | |
| 88342 | <1% | 3,023 | $60K | |
| 88304 | <1% | 2,330 | $57K | |
| 87625 | <1% | 2,041 | $51K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 425 | $44K |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | <1% | 5,442 | $20K |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 1,444 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 253 | $12K |
| 88312 | <1% | 451 | $11K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 84 | $10K |
| 87493 | <1% | 238 | $7K | |
| 88341 | <1% | 115 | $6K | |
| 80053 | Comprehensive metabolic panel | <1% | 421 | $4K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 253 | $4K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 360 | $2K |
| 80061 | Lipid panel | <1% | 321 | $2K |
| 86803 | <1% | 132 | $1K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 45 | $1K |
| 80081 | <1% | 18 | $1K | |
| 86480 | <1% | 20 | $1K | |
| 86592 | <1% | 267 | $768.96 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 126 | $753.99 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 70 | $684.74 |
| 87563 | <1% | 26 | $640.74 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 72 | $620.64 |
| 87088 | <1% | 54 | $583.00 | |
| 87641 | <1% | 14 | $535.08 | |
| 87340 | <1% | 48 | $508.35 | |
| 87081 | <1% | 81 | $454.07 | |
| 83655 | <1% | 39 | $450.06 | |
| 84439 | <1% | 43 | $362.04 | |
| 81001 | <1% | 128 | $345.62 | |
| 85027 | <1% | 61 | $340.99 | |
| 86038 | <1% | 20 | $307.40 | |
| 82607 | <1% | 24 | $280.32 | |
| 87070 | <1% | 42 | $253.26 | |
| 84702 | <1% | 34 | $249.98 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 31 | $249.86 |
| 84153 | <1% | 19 | $243.96 | |
| 87186 | <1% | 19 | $208.81 | |
| 87481 | <1% | 25 | $200.49 | |
| 88300 | <1% | 13 | $165.45 | |
| 83550 | <1% | 16 | $133.28 | |
| 82570 | <1% | 29 | $131.37 | |
| 82728 | <1% | 18 | $128.35 | |
| 82950 | <1% | 27 | $122.31 | |
| 84481 | <1% | 13 | $118.20 | |
| 83540 | <1% | 18 | $111.78 | |
| 85610 | <1% | 29 | $107.22 | |
| 82043 | <1% | 25 | $95.75 | |
| 85652 | <1% | 31 | $79.05 | |
| 84550 | <1% | 16 | $68.80 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 396 | $65.34 |
| 87147 | <1% | 15 | $46.65 | |
| 87077 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTIMMERMAN, LEAH (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.